Rise Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$806K Sell
672
-74
-10% -$75.6K 0.23% 37
2026
Q1
$712K Sell
746
-1
-0.1% -$1.01K 0.25% 37
2025
Q4
$803K Sell
747
-11
-1% -$10.5K 0.29% 32
2025
Q3
$578K Buy
758
+26
+4% +$19.3K 0.21% 43
2025
Q2
$571K Buy
732
+13
+2% +$10.1K 0.23% 38
2025
Q1
$594K Buy
719
+59
+9% +$49.1K 0.26% 34
2024
Q4
$510K Buy
660
+7
+1% +$5.8K 0.25% 40
2024
Q3
$578K Sell
653
-50
-7% -$45K 0.28% 36
2024
Q2
$637K Sell
703
-57
-8% -$45.6K 0.34% 29
2024
Q1
$592K Buy
760
+402
+112% +$286K 0.32% 29
2023
Q4
$209K Hold
358
0.15% 68
2023
Q3
$192K Buy
358
+65
+22% +$33.5K 0.15% 66
2023
Q2
$137K Sell
293
-12
-4% -$5.03K 0.11% 85
2023
Q1
$105K Buy
305
+3
+1% +$1.01K 0.08% 99
2022
Q4
$111K Hold
302
0.09% 96
2022
Q3
$98K Buy
302
+11
+4% +$3.48K 0.08% 91
2022
Q2
$94K Hold
291
0.09% 96
2022
Q1
$83K Hold
291
0.07% 112
2021
Q4
$80.4K Buy
+291
New +$73.8K 0.08% 108

Other funds holding LLY

Rise Advisors's LLY Position: Q2 2026 in Review

Rise Advisors reduced its Eli Lilly (LLY) stake by 9.9% in Q2 2026, selling an estimated $75.6K and leaving 672 shares worth $806K. The position accounts for 0.23% of the portfolio, ranked #37.

Rise Advisors first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 4,601 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Rise Advisors held 672 shares of Eli Lilly worth $806K as of Q2 2026.
  • Rise Advisors sold 74 Eli Lilly shares in Q2 2026, an estimated $75.6K.
  • Eli Lilly made up 0.23% of Rise Advisors's portfolio in Q2 2026, its #37 holding.
  • Rise Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 4,601 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Rise Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.